Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4044 18 F-DOPA PET/CT leading to diagnosis of micro pheochromocytoma

Introduction: Pheochromocytomas are rare neuroendocrine tumors arising from the chromaffin cells of the adrenal medulla. The recent revision in the WHO classification of Endocrine Tumors 2022 has replaced the historical term "nodular hyperplasia" with "micro pheochromocytoma," owing to the presence of similar molecular clonal changes as larger tumors.

Conference:

Presenting Author:

Authors: Roman-Gonzalez A, Arias L, Castellano A, Toro J, Vega I,

Keywords: Pheochromocytoma, PET-CT, Paraganglioma, NGS,

#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover

Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raymond E

Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,

Keywords: sutent, OS,

#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results

Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Baudin E, Wolin E, Castellano D, Kaltsas G, Lebrec J,

Keywords: mTOR, everolimus, octreotide, 5-hydroxyindoleacetic acid, 5-HIAA,

#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)

Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,

Keywords: targeted therapy, sorafenib, bevacizumab,

#232 Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)

Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Martin-Perez E, Capdevila J, Castellano D, Jiménez-Lacave A, Beguiristain-Gómez A,

Keywords: pancreatic neuroendocrine tumors, gastrinoma, glucagonoma, insulinoma, registry, survival, treatment,